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Poster Session I 35Depending on the definition used, approximately 50% of patients
satisfied criteria for engraftment syndrome. Earlier and more ag-
gressive use of corticosteroids may be associated with less compli-
cated post-transplant courses. Median overall survival has not
been reached; the treatment related mortality was 3%. In addition,
important clinical improvements and reductions in plasma VEGF
levels can occur in the absence of significant decrease in the mono-
clonal protein. Conclusions: Unraveling the mechanisms of the
syndrome both in the context of ASCTand in general are challenges
for the future.88
OUTCOME AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR
MULTIPLE MYELOMA IN PATIENTS WITH PRECEEDING PLASMA CELL
DISORDERS
Kumar, S., Dingli, D., Dispenzieri, A., Lacy, M., Hayman, S.,
Buadi, F., Rajkumar, S.V., Litzow, M.R., Gertz, M.A. Mayo Clinic,
Rochester, MN.
Background: Nearly a third of patients with newly diagnosed
myeloma (MM) have a preceding diagnosis of plasma cell prolifer-
ative disorder (PCPD), mostly monoclonal gammopathy of unde-
termined significance (MGUS), smoldering multiple myeloma
(SMM) or plasmacytoma. While high dose therapy improves sur-
vival in patients with myeloma, it is not clear if patients with preced-
ing PCPD have a different outcome. Methods and Results: We
identified 151 patients with preceding PCPD from among 804
patients undergoing high dose therapy at our institution. These
included 59 patients (7.3%) who had a preexisting diagnosis of
MGUS, 88 (11%) patients, in whom the diagnosis of MM was pre-
ceded by SMM, including 23 patients who also had a preceding
MGUSor plasmacytoma. In addition, 27 (3.4%) patients gave a pre-
ceding history of plasmacytoma. Themedian duration from the first
diagnosis of a PCPD to that of myeloma was 32.4 months (range,
6.1 to 31 years), and was longer for patients with an initial diagnosis
ofMGUS compared to those with out precedingMGUS.While re-
sponse rates including complete responses were generally similar
between the two groups of patients, those with any preceding
PCPD had a median TTP of 24.2 months (95% CI; 20, 28.3) com-
pared to 17.3 (95% CI; 15.7, 18.8) months for those with no previ-
ous history (De novo Myeloma); p 5 0.01. The median OS from
transplant for patients with previous history was 63.7 months
(95% CI; 50.2, 77.4) compared to 48.3 months (95% CI; 39.7,
56.9) for the de novo group, p 5 0.01. These differences were
most striking for those with a preceding diagnosis of MGUS; who
had a longer time to progression (27.6 months vs. 17.7 months;
p 5 0.02), and longer OS from transplant (80.2 months vs. 49.3
months, p 5 0.046) compared to those without any preceding
MGUS. In a multivariate analysis, transplant within 12 months of
diagnosis, lower serum M-protein at transplant, PCLI\1%, ab-
sence of cytogenetic abnormalities, achievement of CR, and pres-
ence of any preexisting monoclonal disorder prior to diagnosis of
myeloma were independently prognostic for risk of post transplant
relapse.Conclusion: Patients with preexisting PCPD at the time of
myeloma diagnosis undergoing HDT has a better outcome reflect-
ing more indolent disease and a favorable biology than those pre-
senting with de novo myeloma and no antecedent plasma cell
dyscrasia.89
EARLY LYMPHOCYTE RECOVERY PREDICTS SUPERIOR SURVIVAL AF-
TER AUTOLOGOUS STEM CELL TRANSPLANTATION IN NON-HODGKIN
LYMPHOMA: A PROSPECTIVE STUDY
Porrata, L.F., Inwards, D.J., Ansell, S.M., Micallef, I.N.,
Johnston, P.B., Gastineau, D.A., Litzow, M.R., Markovic, S.N. Mayo
Clinic College of Medicine, Rochester, MN.
Background: Day 15 absolute lymphocyte count (ALC-15)
$500 cells/ml after autologous peripheral blood hematopoietic
stem cell transplantation (APHSCT) is a significant predictor for
survival. Limitations of previous reports have been their retrospec-
tive nature and no ALC-15 lymphocyte subsets analysis. Thus, from2/2002 until 2/2007, 50 non-Hodgkin lymphoma (NHL) patients
were enrolled in a prospective study to address these limitations.
Methods: APHSCT eligible NHL patients who signed written
consent for additional blood collections participated in the study.
The primary end point was to confirm the ALC-15 survival role
and to identify the lymphocyte subsets of greatest impact on
ALC-15 after APHSCT. Results: The median age of the cohort
was 57.7 years (range: 23–73). The groups (ALC-15 $500 vs\
500 cells/ml) were balanced to lymphoma type (p 5 0.4), gender
(p5 0.5), age (p5 0.2), extranodal sites (p 5 0.4), lactate dehydro-
genase (p 5 0.5), performance status (p 5 0.5), stage (p 5 0.5), in-
ternational prognostic index (p 5 0.9), number of prior
chemotherapies (p 5 0.1), clinical status at APHSCT (p 5 0.2),
and infused CD34/kg (p 5 0.8). With a median follow-up of 22.2
months (range: 6–63.7 months), patients with an ALC-15 $500
cells/ml (n5 35) experienced superior overall survival (OS) and pro-
gression-free survival (PFS) compared with those who did not (me-
dianOS: not reached vs 19months, 3 years OS rates of 80% vs 40%,
p\ 0.0004; median PFS: not reached vs 3.4 months, 3 years PFS
rates of 60% vs 14%, p\ 0.0001, respectively). By day 15 post-
APHSCT 30% of patients achieved a normal CD3, 18% a normal
CD4, 38% a normal CD8, 4% a normal CD19, and 76% a normal
[CD161/561/CD3-] counts. In Univariate analysis CD161/561/
CD3- natural killer (NK) cells were the only ALC-15 lymphocyte
subset that predicted for survival. Patients with a normal absolute
NK cell count ($80 cells/ml, n 5 38) experienced superior OS
and PFS compared with those who did not (medianOS: not reached
vs 5 months, 3 years OS rates of 76% vs 36%, p\0.0001; and me-
dian PFS: not reached vs 3 months, 3 years PFS rates of 57% vs 9%,
p \ 0.0001, respectively). Conclusion: This study confirms the
prognostic ALC-15 survival role and identifies NK cells as the
key lymphocyte subset affecting clinical outcomes after APHSCT
in NHL. This study was supported in part by the Grant
CA90628–04A from the National Institute of Health, and the Uni-
versity of Iowa/Mayo Clinic Lymphoma Spore CA97274.90
AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN FIRST REMISSION
FOR PATIENTS WITH MANTLE CELL LYMPHOMA IS ASSOCIATED WITH
PROLONGED SURVIVAL
Siddiqui, M.A., Johnston, P.B., Inwards, D.J., Ansell, S.M.,
Porrata, L.F., Micallef, I.N. Mayo Clinic, Rochester, MN.
Mantle cell lymphoma (MCL) is associated with a median sur-
vival of less than 5 years and is incurable with conventional chemo-
therapy, therefore more aggressive therapy in the form of stem cell
transplantation is often recommended. Patients receiving an autol-
ogous stem cell transplantation (ASCT) forMCLbetween 1993 and
2006 at Mayo Clinic Rochester were reviewed. 63 patients were
identified, and their baseline characteristics at diagnosis included
the following: median age 54 years (range 36–69), 51 are male, 12
are female; 55 patients had stage III or IV disease. The majority
of patients had a good PS and low IPI. Median follow up from di-
agnosis is 59.8 months (range 15 months – 20.5 years) and from
ASCT is 36.5 months (range 4months – 10.8 years). Thirty-two pa-
tients underwent ASCT in first CR/PR and 31 patients in second or
greater remission. Median overall survival (OS) from ASCT for the
patients in first remission was 91.7 months and for the patients be-
yond first remission was 35.6 months (p 5 0.01). Median OS from
diagnosis for the patients who underwent ASCT in first remission
was 103.8 months and for the patients transplanted beyond first re-
mission was 64.0 months (p 5 0.17). Median progression free sur-
vival (PFS) from ASCT was 29.6 months for the patients
transplanted in first remission vs. 15.3 months (p5 0.03) for the pa-
tients transplanted beyond first remission. Disease status at trans-
plant appears to be the most significant factor affecting survival.
Our data suggests that for patients in whom ASCT is being consid-
ered, it is advisable to proceed early in the disease (first remission)
and not wait for relapse. Demonstration of improved cohort
survival in those transplanted in first remission vs. a strategy of
transplant at chemotherapy sensitive relapse would require a ran-
domized prospective trial.
